ATF1 Antibody

What is ATF1 and why is it significant in molecular research?

ATF1 is a transcription factor belonging to the ATF subfamily of the bZIP family, also known as protein TREB36. It regulates gene expression related to cell growth, survival, and stress response pathways. ATF1's significance stems from its dual functionality: it operates through both DNA-binding dependent mechanisms (as a transcription factor) and DNA-binding independent processes (through protein-protein interactions).

The protein is phosphorylated at serine 63 in its kinase-inducible domain by several serine/threonine kinases, including cAMP-dependent protein kinase A and cyclin-dependent kinase 3 (CDK3). This phosphorylation enhances its transactivation and transcriptional activity, thereby affecting cellular transformation processes . Additionally, ATF1 can bind DNA as a heterodimer, preferentially with another bZIP protein (Pcr1), which influences its target selection and regulatory function .

What types of ATF1 antibodies are available for research applications?

Researchers can access several types of ATF1 antibodies with varying properties:

The rabbit anti-human ATF1 antibody recognizes cyclic AMP-dependent transcription factor ATF1 and is prepared by repeated immunization with highly purified antigen . The mouse monoclonal antibody (clone ATF1 2A9/8) was developed using yeast transcription factor ATF1 as an immunogen . The goat anti-human/mouse ATF1 antibody is derived from E. coli-expressed recombinant human ATF1 (Met1-Val271) . Each antibody offers specific advantages for different experimental systems.

What applications are validated for ATF1 antibodies?

ATF1 antibodies have been validated for multiple research applications:

Western Blotting (WB): ATF1 antibodies detect a specific band at approximately 48 kDa in whole cell lysates, cytoplasmic fractions, and nuclear extracts. For optimal results, loading 30 μg of whole cell lysate, 20 μg of cytoplasmic extract, or 10 μg of nuclear extract is recommended, with ATF1 being most enriched in nuclear fractions .

Chromatin Immunoprecipitation (ChIP): Antibodies like the mouse monoclonal ATF1 2A9/8 have been validated for ChIP applications, allowing researchers to study ATF1's DNA binding patterns and genomic targets .

Immunohistochemistry (IHC): Several ATF1 antibodies can be used for tissue localization studies, helping researchers examine expression patterns across different tissue types and disease states .

Immunoprecipitation (IP): ATF1 antibodies effectively pull down ATF1 and its interacting partners, enabling the study of protein complexes. This has been crucial for discovering non-canonical functions of ATF1, such as its interaction with APC/C components .

How should phosphorylation states of ATF1 be considered when selecting antibodies?

When studying ATF1's phosphorylation states, researchers need to consider several methodological factors:

Antibody selection: Distinct antibodies recognize different phosphorylation states of ATF1. For example, phospho-specific antibodies that recognize p-ATF1-T184 are critical for studying its role in metastasis and MMP2 regulation . When designing experiments to investigate ATF1 activation, researchers must determine whether total ATF1 or a specific phosphorylated form is relevant to their hypothesis.

Experimental design considerations:

• Include phosphatase inhibitors in lysis buffers to preserve phosphorylation states

• Run parallel samples with phosphatase treatment as controls

• Consider time-course experiments to capture dynamic phosphorylation changes

• Include positive controls where phosphorylation is stimulated (e.g., through PKA activation for Ser63 phosphorylation)

Validation approach: When using phospho-specific antibodies, validate specificity through phosphatase treatment or phospho-mimetic/phospho-dead mutants. This confirms that the observed signal genuinely represents the phosphorylated form of ATF1 rather than cross-reactivity with related proteins.

What are the critical controls when using ATF1 antibodies in protein-protein interaction studies?

When investigating ATF1's interactions with other proteins (such as APC/C components), implement these essential controls:

Input controls: Always analyze a portion of the pre-immunoprecipitation lysate to confirm target protein expression. As demonstrated in studies of ATF1-APC/C interactions, this helps interpret pull-down efficiency .

Negative controls:

• Use isotype-matched IgG from the same species as the ATF1 antibody

• Include lysates from ATF1-depleted cells (siRNA or CRISPR knockout)

• For GST-tagged experiments, include GST-only controls to identify non-specific binding

Reciprocal co-IP: Confirm interactions by pulling down with antibodies against both ATF1 and its suspected binding partner. The interaction between ATF1 and APC/C was validated by both anti-ATF1 immunoprecipitation showing Apc5 and GST-Atf1 pull-down showing Apc5-HA .

Competition assays: Pre-incubate with purified recombinant ATF1 to demonstrate specific antibody binding and to block non-specific interactions.

Crosslinking considerations: For transient interactions, consider using chemical crosslinkers before lysis, particularly for studying dynamic complexes like ATF1 with APC/C components .

How can researchers distinguish between ATF1's transcriptional and non-transcriptional functions?

Recent research has revealed that ATF1 has functions beyond its classical role as a DNA-binding transcription factor. To differentiate these functions:

Domain mutant approach: Create and express ATF1 mutants lacking functional bZIP domains to specifically study DNA-binding independent functions. Research has shown that ATF1 can suppress the temperature-sensitive phenotype of apc5-1 mutants independently of its bZIP domain, indicating a separate function in activating APC/C .

Subcellular fractionation: Analyze ATF1 distribution across nuclear, cytoplasmic, and other cellular compartments. While transcriptional functions occur in the nucleus, non-transcriptional functions like APC/C activation may involve different localizations or trafficking patterns.

Functional assays:

• For transcriptional functions: Use reporter assays with ATF1 binding sites

• For APC/C activation functions: Employ in vitro ubiquitylation assays to directly assess ATF1's ability to stimulate APC/C activity toward substrates like cyclin B and securin

• For phosphorylation-dependent functions: Use phospho-specific antibodies to determine whether specific post-translational modifications correlate with different functional outcomes

Combined approaches: Use ChIP to identify DNA-binding targets while simultaneously performing co-IP to identify protein interaction partners, allowing comprehensive mapping of ATF1's functional network.

Why might Western blots with ATF1 antibodies show multiple bands, and how should these be interpreted?

Multiple bands in ATF1 Western blots may result from several factors that require careful interpretation:

Post-translational modifications: Phosphorylation of ATF1 at sites like serine 63 or threonine 184 can cause mobility shifts . If treating samples with lambda phosphatase eliminates certain bands, this confirms they represent phosphorylated forms.

Cross-reactivity: Some ATF1 antibodies may recognize related ATF/CREB family members. The ATF1 gene of S. pombe shows strong homology to mammalian ATF2 , which could lead to cross-recognition. Compare band patterns with recombinant protein standards and genetic knockout controls.

Degradation products: ATF1 may undergo proteolytic processing during sample preparation or as part of its biological regulation. Include protease inhibitors in lysis buffers and prepare samples fresh to minimize this possibility.

Verification approaches:

• Compare subcellular fractions (ATF1 should be enriched in nuclear extracts)

• Use different antibodies recognizing distinct epitopes

• Include siRNA knockdown controls to identify specific bands

• For the canonical full-length ATF1, expect a band at approximately 48 kDa

What strategies can overcome weak or inconsistent ATF1 antibody signals?

When facing detection challenges with ATF1 antibodies, implement these methodological solutions:

Sample preparation optimization:

• Enrich nuclear fractions where ATF1 is concentrated

• Use optimized lysis buffers with appropriate detergent concentrations

• Include protease and phosphatase inhibitor cocktails

• Avoid repeated freeze-thaw cycles of samples

Antibody optimization:

• Titrate antibody concentrations (1 μg/mL is recommended for some Western blot applications)

• Extend primary antibody incubation time (overnight at 4°C often improves signal)

• Test different blocking agents (BSA vs. milk protein)

• Try different detection systems (HRP-conjugated vs. fluorescent secondaries)

Signal enhancement techniques:

• Use signal amplification systems for low-abundance detection

• For Western blots, longer exposure times or more sensitive substrates

• For IHC/IF, employ tyramide signal amplification when appropriate

Epitope accessibility improvements:

• For fixed samples, optimize antigen retrieval methods

• Consider alternative fixation approaches that may better preserve the epitope

• Test both reducing and non-reducing conditions for Western blotting

How can ATF1 antibodies be utilized to study ATF1's role in cancer progression?

ATF1 antibodies provide valuable tools for investigating ATF1's contributions to cancer:

Expression and phosphorylation analysis: Recent research demonstrates that phosphorylated ATF1 at Thr184 (p-ATF1-T184) promotes metastasis in gastric cancer. Using phospho-specific antibodies, researchers can assess this modification's presence across cancer types and stages .

Mechanistic investigations: ATF1 regulates Matrix metallopeptidase 2 (MMP2), which facilitates tumor cell invasion. Researchers can use ChIP with ATF1 antibodies to analyze this transcriptional regulation, combined with functional assays like wound scratch tests and Transwell assays to assess invasive potential .

Clinical correlation studies: Immunohistochemical analysis with ATF1 antibodies can determine whether expression levels or phosphorylation states correlate with clinicopathological characteristics and patient outcomes. This approach has identified p-ATF1-T184 as a potential biomarker in gastric cancer .

Therapeutic target assessment: Based on the finding that ATF1 activates the APC/C independently of its DNA-binding domain , researchers can use antibodies to monitor ATF1-APC/C interactions after treatment with potential inhibitors, potentially developing new cancer therapeutics.

How can researchers study the APC/C-activating function of ATF1 using antibodies?

The discovery that ATF1 physically interacts with and activates the APC/C ubiquitin ligase independently of its DNA-binding capability represents a novel function . To investigate this:

Co-immunoprecipitation approaches:

• Pull down ATF1 and probe for APC/C components like Apc5

• Reciprocally, immunoprecipitate APC/C subunits and detect ATF1

• Include controls to demonstrate specificity, such as GST-only versus GST-ATF1 comparisons

In vitro ubiquitylation assays:

• Purify ATF1 (wild-type and bZIP domain mutants)

• Add purified ATF1 to cell-free systems containing APC/C

• Assess ubiquitylation of known APC/C substrates like cyclin B and securin

• Compare activity with and without ATF1 addition

Genetic complementation experiments:

• Express ATF1 in temperature-sensitive APC/C mutant cells (apc5-1)

• Test whether this rescues the mutant phenotype

• Compare rescue efficiency between wild-type ATF1 and bZIP domain mutants

Domain mapping:

• Create truncated versions of ATF1 to identify the minimal region required for APC/C interaction

• Use these constructs in pull-down assays to map the binding interface

What experimental designs best capture the dynamics of ATF1 phosphorylation?

To study the dynamic nature of ATF1 phosphorylation:

Time-course experiments:

• Stimulate cells with relevant inducers (stress conditions, growth factors)

• Collect samples at multiple timepoints

• Use phospho-specific antibodies to track kinetics of different modifications

• Correlate phosphorylation changes with functional outcomes

Phosphorylation site mutant studies:

• Create phospho-mimetic (e.g., T184D) and phospho-deficient (e.g., T184A) mutants

• Express these in appropriate cellular contexts

• Compare their ability to rescue phenotypes in ATF1-depleted cells

• Assess their interaction with binding partners like APC/C or regulation of targets like MMP2

Mass spectrometry validation:

• Immunoprecipitate ATF1 with validated antibodies

• Analyze by mass spectrometry to identify all phosphorylation sites

• Quantify changes in phosphorylation stoichiometry under different conditions

• This approach has been used to identify upstream kinases that phosphorylate ATF1 at Thr184

Combined ChIP and phospho-antibody approaches:

• Perform ChIP with phospho-specific antibodies

• Determine whether specific phosphorylated forms of ATF1 preferentially associate with particular genomic regions

• Correlate this with transcriptional outcomes of target genes

How might ATF1 antibodies contribute to understanding its role in the DNA damage response?

Research on ATF1's mammalian homolog ATF2 has revealed a role in DNA damage response through interaction with TIP60 and the Cul3/Roc1 ubiquitin ligase . Similar investigations with ATF1 could be pursued using:

Co-localization studies:

• Use ATF1 antibodies for immunofluorescence before and after DNA damage

• Examine co-localization with DNA damage markers (γH2AX, 53BP1)

• Track potential relocalization or change in phosphorylation state

Protein complex identification:

• Immunoprecipitate ATF1 after DNA damage

• Analyze interacting partners by mass spectrometry

• Compare to unstressed conditions to identify damage-specific interactions

Functional genetic screens:

• Combine ATF1 antibodies with CRISPR screens targeting DNA damage response genes

• Identify genetic dependencies that specifically affect ATF1 phosphorylation or localization

• Validate hits with individual knockouts and rescue experiments

Chromatin association dynamics:

• Perform ChIP-seq with ATF1 antibodies before and after DNA damage

• Identify damage-responsive binding sites

• Correlate with transcriptional changes of stress-responsive genes

What methodological advances might improve ATF1 detection in challenging samples?

For researchers working with difficult samples or seeking higher sensitivity:

Single-cell techniques:

• Adapt ATF1 antibodies for single-cell western blotting

• Develop CyTOF (mass cytometry) approaches using metal-conjugated ATF1 antibodies

• Apply proximity ligation assays to visualize specific ATF1 interactions in situ

Proximity-based labeling:

• Combine ATF1 antibodies with BioID or APEX2 proximity labeling

• Identify proteins in close proximity to ATF1 under various conditions

• Map the dynamic ATF1 interactome in different cellular compartments

Advanced imaging techniques:

• Super-resolution microscopy with ATF1 antibodies

• Live-cell imaging using cell-permeable antibody fragments

• Fluorescence correlation spectroscopy to study ATF1 dynamics

Nanoparticle-based detection:

• Conjugate ATF1 antibodies to quantum dots or gold nanoparticles

• Develop multiplexed detection systems for simultaneous analysis of multiple phosphorylation states

• Improve signal-to-noise ratios in complex tissue samples